Prof. PeptideProf. Peptide

Ipamorelin

Growth HormoneResearch-Grade

Last reviewed: September 20, 2026

Quick Facts

What it is
A lab-made peptide that signals the pituitary to release the body's own growth hormone — the most selective of the growth-hormone-releasing peptides, studied for recovery, lean mass, and sleep.
How it's taken
Subcutaneous injection, most often at bedtime
Half-life
~2 hours
Typical research dose
200–300 mcg, one to three times daily, in 8–12 week cycles
Research status
Not FDA-approved — research use only.
On this page
  1. 1.Where to source Ipamorelin
  2. 2.What is Ipamorelin?
  3. 3.How does Ipamorelin work?
  4. 4.What is Ipamorelin used for?
  5. 5.How long does Ipamorelin take to work?
  6. 6.How is Ipamorelin dosed?
  7. 7.How is Ipamorelin administered?
  8. 8.What does Ipamorelin stack well with?
  9. 9.What are the side effects of Ipamorelin?
  10. 10.Does Ipamorelin interact with other drugs?
  11. 11.How should Ipamorelin be stored?
  12. 12.What are the limitations of Ipamorelin research?
  13. 13.Ipamorelin FAQ
  14. 14.References
  15. 15.Published Studies

Where to source Ipamorelin

Ipamorelin is not FDA-approved for any human use and is sold only as a research-grade peptide. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes — including pre-mixed CJC-1295/Ipamorelin combo options for the canonical GH Stack pairing.

Capstone Peptides50% off
Professor's Pick

Accumark Labs · digital COAs

Shop Capstone Peptides
Amino Club40% off

ILS Laboratories · batch COAs

Shop Amino Club
Peptide Partners10% off
Professor's Pick

Kovera, Chromate and BioRegen · certificates checked at each lab

Shop Peptide Partners
Glacier Aminos10% off

Batch-traceable COAs · cold-chain shipping

Shop Glacier Aminos
Compare prices across 48 vendors

Also stocking Ipamorelin

EZ Peptides, Fusion Peptide, GenPeptide, Healius Peptides — each carries a current price row for this compound.

Compare all 48 vendors stocking Ipamorelin

See all 88 verified vendors

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed by Novo Nordisk in the late 1990s as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR-1a). It is also known by its developmental code NNC 26-0161. Unlike other GHRPs (GHRP-2, GHRP-6), ipamorelin stimulates growth hormone release without elevating cortisol, prolactin, ACTH, FSH, LH, or TSH — making it the most selective GHRP available. It was investigated in Phase 2 trials for postoperative ileus but discontinued for lack of efficacy in that specific indication. Often paired with CJC-1295 as the GH Stack — the two activate different receptor pathways and produce synergistic GH release. New to peptide research? Start with the basics

Reported benefits:

  • Stimulates pulsatile growth hormone release via the ghrelin receptor pathway
  • Highly selective for GH — does not affect cortisol, prolactin, or other pituitary hormones
  • Increases IGF-1 levels through GH-mediated pathway
  • Supports lean muscle growth and fat reduction (downstream of GH)
  • Improved sleep quality reported, especially with bedtime dosing
  • Bone formation support (counters glucocorticoid-induced bone loss in animal models)

Common research dose: Most research protocols use 200–300 mcg subcutaneously, 1–3 times daily. Bedtime dosing is most common to align with natural GH circadian peaks. Cycle length is typically 8–12 weeks. Empty-stomach dosing is required for full GH response.

Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.

How does Ipamorelin work?

Ipamorelin selectively binds the ghrelin/growth hormone secretagogue receptor (GHSR-1a) on pituitary somatotrophs, triggering pulsatile GH release through the cAMP/PKA pathway. Unlike GHRP-2 and GHRP-6, ipamorelin does NOT stimulate cortisol, ACTH, prolactin, or TSH — even at doses 200x above the GH-releasing dose. This selectivity is its primary clinical advantage and the reason it pairs cleanly with CJC-1295 (which works through a different receptor) for synergistic GH release.

  1. GHSR-1a Receptor Activation [1]. Ipamorelin selectively binds the growth hormone secretagogue receptor (GHSR-1a, the ghrelin receptor) on pituitary somatotroph cells and hypothalamic neurons. This is the same receptor activated by endogenous ghrelin — ipamorelin acts as a synthetic ghrelin mimic with much greater receptor selectivity.
  2. cAMP/PKA Signaling [2]. Receptor activation triggers a Gαq-coupled signaling cascade that increases intracellular calcium and cAMP production, activating protein kinase A. This drives the synthesis and release of stored growth hormone from somatotrophs.
  3. Pulsatile GH Release [1]. Ipamorelin amplifies the natural pulsatile pattern of GH secretion rather than creating a continuous flood. This preserves the hypothalamic-pituitary feedback loops that regulate GH homeostasis, which is mechanistically safer than direct GH administration.
  4. Selectivity for GH [1][3]. Unlike GHRP-2 and GHRP-6, ipamorelin does NOT stimulate cortisol, ACTH, prolactin, FSH, LH, or TSH release. Even at doses 200x higher than the GH-releasing dose, no meaningful effect on these other hormones is observed. This selectivity is its primary clinical advantage.
  5. Somatostatin Antagonism [4]. Ipamorelin reduces the inhibitory effect of somatostatin (GH-inhibiting hormone), allowing the pituitary's GH-releasing activity to remain elevated longer than it would otherwise.

What is Ipamorelin used for?

Ipamorelin's research evidence base spans GH stimulation (animal and human PK studies), body composition (downstream of GH/IGF-1), bone formation (counters glucocorticoid-induced bone loss), postoperative ileus (Phase 2, primary endpoint not met), and cognitive/sleep applications. Most evidence is from animal models and the discontinued Phase 2 program; long-term controlled human trials are limited.

  1. Growth Hormone Stimulation [1][3]. Multiple animal and human studies confirm ipamorelin produces GH release with potency comparable to GHRP-6 but greater selectivity. Effects observed in primary rat pituitary cells (EC50 ~1.3 nmol/L) and pentobarbital-anaesthetized rat models.
  2. Body Composition Research. IGF-1 elevation downstream of ipamorelin-induced GH release supports lean muscle synthesis and lipolysis. Most ipamorelin body composition data comes from clinical practice rather than controlled trials.
  3. Bone Formation [4]. In adult female rats, ipamorelin counteracted glucocorticoid-induced decreases in bone formation. The GH secretagogues ipamorelin and GHRP-6 increased bone mineral content in adult female rats.
  4. Postoperative Ileus (Phase 2). Helsinn Therapeutics tested ipamorelin in Phase 2 trials for postoperative ileus. In the Beck 2014 trial (114 patients, IV dosing for up to 7 days) it missed its primary endpoint (25.3 vs 32.6 hours to first tolerated meal, p=0.15); treatment-emergent adverse events occurred in 87.5% on ipamorelin vs 94.8% on placebo, and the authors reported it as well tolerated. A second Phase 2 trial (NCT01280344, n=320) completed with no results posted. FDA's compounding safety-risk list cites a published report of serious adverse events, including death, with intravenous ipamorelin for gastric motility.
  5. Cognitive and Sleep Research. Anecdotal and clinical observations suggest improved sleep quality with bedtime dosing, likely due to alignment with natural GH circadian peaks. Limited controlled human data.

How long does Ipamorelin take to work?

Ipamorelin effects build over weeks of consistent dosing. Most users notice improved sleep within 1–2 weeks. Body composition changes (increased lean mass, reduced fat) typically emerge over 8–12 weeks. IGF-1 elevation can be measured within days of starting therapy. Half-life is short — a human PK study (Gobburu et al., 1999, Pharmaceutical Research) reports approximately 2 hours — so effects depend on consistent dose timing rather than sustained blood levels.

Most users notice improved sleep quality within 1–2 weeks of consistent bedtime dosing — often the first noticeable subjective effect. Body composition changes (increased lean mass, reduced fat) typically emerge over 8–12 weeks. IGF-1 elevation can be measured in blood work within days of starting therapy. Half-life is short — a human PK study (Gobburu et al., 1999, Pharmaceutical Research) reports approximately 2 hours — so effects depend on consistent timing rather than sustained blood levels; bedtime dosing on that reasoning is a commonly reported research convention, not itself trial-tested.

How is Ipamorelin dosed?

No human trial has established a subcutaneous research-use dose for ipamorelin. The figures below are split into what the cited literature administered and, separately, community-reported practice.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

What the cited literature administered

Human trial (dose-escalation PK/PD). Gobburu et al. (Pharm Res, 1999, PMID 10496658) tested ipamorelin in 40 healthy male volunteers (8 per dose level) using five ascending doses — 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg — given as a 15-minute intravenous infusion, not a subcutaneous injection. Converting the paper’s own nmol/kg figures by ipamorelin’s molecular weight gives roughly 3–100 mcg/kg across the five dose levels. GH release was dose-dependent up to a plateau, peaking at 40 minutes post-dose and declining to baseline within a few hours, consistent with the compound’s 2-hour terminal half-life reported in the same trial. No adverse events beyond the expected transient GH/IGF-1 rise are reported in the paper’s own results.

Human trial (repeated-dose, postoperative ileus). Beck et al. (Int J Colorectal Dis, 2014, PMID 25331030, NCT00672074), a multicenter, double-blind, placebo-controlled Phase 2 trial in 114 hospital patients recovering from bowel resection surgery, gave intravenous ipamorelin at 0.03 mg/kg twice daily for up to 7 days — also not a subcutaneous dose, and in a surgical-recovery population rather than healthy volunteers. Any treatment-emergent adverse event occurred in 87.5% of the ipamorelin group versus 94.8% of the placebo group; the paper concludes this dose was well tolerated over up to 7 days. The trial missed its primary endpoint: median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo (p=0.15). A second Phase 2 trial, NCT01280344 (n=320), completed with no results posted.

Community-reported practice (unverified)

Reported research-community practice — attributed to where it circulates, not to the trial above, and not independently verified by Prof. Peptide — is 200–300 mcg subcutaneously per injection, most often at bedtime, sometimes 2–3 times daily. This diverges from the cited trial in both route (subcutaneous versus the trial’s intravenous infusion) and dose basis (a flat mcg figure versus the trial’s own weight-based nmol/kg dosing) — no source was found deriving the community figure from the trial’s own numbers. A commonly reported cycle length is 8–12 weeks on with at least 4 weeks off.

Ipamorelin is frequently stacked with CJC-1295 (with or without DAC). The combination is reported to produce greater GH release than either alone because they activate different receptor pathways simultaneously — ipamorelin via GHSR-1a, CJC-1295 via GHRH receptor. See the GH Stack page for the combined protocol.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule. The Ipamorelin reconstitution calculator works the same arithmetic against the vial sizes tracked for this compound.

Common question: How often are CJC-1295 and Ipamorelin dosed?

How is Ipamorelin administered?

Ipamorelin is given as a subcutaneous injection — under the skin, not into muscle — 1–3 times daily using a small insulin syringe. Bedtime dosing aligns with the natural overnight GH peak. Empty-stomach timing maximizes the GH response — insulin from food blunts GH release. For the practical mechanics of insulin syringes, units vs mcg conversion, and subcutaneous technique, see the syringes and injection technique guide.

  1. Route. Subcutaneous injection. Common sites: abdomen, thigh, upper arm.
  2. Time of day. Bedtime is most common. Reported protocols inject 30–60 minutes before sleep on an empty stomach.
  3. With or without food. Best on empty stomach (2+ hours after eating, no food for 30 min after) to maximize GH release. Food spikes insulin, which blunts GH secretion.
  4. Site rotation. Rotating sites each injection, with at least an inch between consecutive sites, is the convention for limiting localized irritation.
  5. Hunger spike. Brief increase in appetite is expected for 30–60 minutes after injection (ghrelin receptor activation). Bedtime dosing lets you sleep through this.
  6. Missed dose. Reported practice skips and resumes at the next scheduled dose. The convention is not to double-dose.
  7. Cycle structure. Community-reported, not trial-derived: 8–12 weeks on, 4+ weeks off.

Timing context. Ipamorelin's 2-hour half-life means each dose produces a discrete GH pulse rather than sustained elevation. The body's largest natural GH release happens in the first 90 minutes of deep sleep — bedtime dosing (30–60 min before sleep) stacks the ipamorelin pulse onto this natural peak. Empty-stomach timing matters more than time of day in absolute terms: insulin secreted in response to food blunts the GH response substantially.

AspectReported
FrequencyContinuous ghrelin-receptor-agonist exposure is documented to desensitize the receptor (Camiña et al., 2004, Endocrinology) — the real mechanism cited as the reason to cycle. The specific interval reported here is community practice, not itself trial-derived: 1–3× daily, most users dosing once at bedtime, cycled rather than continuous
Best time of dayThe most reproducible endogenous GH pulse occurs shortly after sleep onset, coinciding with slow-wave sleep — established sleep endocrinology (Van Cauter & Plat, 1996, J Clin Endocrinol Metab); bedtime dosing on that reasoning is a commonly reported research convention, not itself trial-tested.
FoodEmpty stomach required — 2+ hours after eating, 30+ min before next meal
Injection site rotationRotating between the abdomen, thigh, and upper arm without reusing the same site for the next injection is standard subcutaneous-injection practice — documented in FDA-approved injectable labels generally (e.g., Wegovy's and Mounjaro's own instructions to rotate with each dose), not specific to Ipamorelin.
Half-life~2 hours
Steady-statePer-pulse effect rather than traditional steady-state — each dose triggers a discrete GH pulse

Reconstitution math. Water volume sets concentration: a lower volume yields a higher concentration and a smaller syringe draw for a given mg amount, and the reverse for a higher volume. Ipamorelin research vials are typically 5 mg. Because doses are small (200–300 mcg), 2 mL or 3 mL reconstitution is common — it gives more precise unit draws at low dose. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 5 mg vial.

BAC waterConcentration100 mcg dose200 mcg dose300 mcg dose500 mcg dose
1 mL5 mg/mL2 units4 units6 units10 units
2 mL2.5 mg/mL4 units8 units12 units20 units
3 mL1.67 mg/mL6 units12 units18 units30 units

Units vs mcg. At a 5 mg vial, each unit drawn delivers 50 mcg of Ipamorelin at 1 mL reconstitution, 25 mcg at 2 mL, and 16.7 mcg at 3 mL — the reconstitution volume determines the mcg-per-unit conversion. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.

What does Ipamorelin stack well with?

Ipamorelin's canonical pairing is CJC-1295 — the dual-pathway GH Stack (ghrelin receptor + GHRH receptor) produces synergistic GH release greater than either alone. The recovery peptides (BPC-157, TB-500) pair cleanly for systemic recovery during anabolic protocols. IGF-1 LR3 stacks for direct receptor activation alongside endogenous GH stimulation — space injections 2–3 hours apart to avoid receptor competition. Other GHRPs (GHRP-2, GHRP-6, MK-677) are redundant by the same ghrelin-pathway mechanism.

  1. CJC-1295 (GH Stack). The most popular pairing. CJC-1295 activates the GHRH receptor while ipamorelin activates the ghrelin receptor — dual-pathway activation produces synergistic GH release. See the GH Stack page for the combined protocol.
  2. BPC-157 / TB-500. Wolverine Stack paired for recovery support. The healing peptides accelerate tissue repair while ipamorelin supports the GH-driven anabolic environment.
  3. IGF-1 LR3. IGF-1 LR3 combined for direct IGF-1 receptor activation alongside endogenous GH stimulation. Reported protocols separate IGF-1 LR3 from ipamorelin by at least 2–3 hours, citing receptor competition as the reason.
  4. Resistance training. Natural pairing — exercise-induced GH release is amplified when paired with ipamorelin's pulse.
  5. Conflicts: other GHRPs. GHRP-2, GHRP-6, and MK-677 all activate the same ghrelin receptor — combination is redundant with no additive benefit.

What are the side effects of Ipamorelin?

Ipamorelin is selective: it does NOT raise cortisol (a problem with GHRP-2 and GHRP-6) and does not affect prolactin or other pituitary hormones. The most-reported user effects are mild injection-site reactions and a brief hunger spike (ghrelin receptor activation, 30–60 minutes post-injection). Long-term safety data beyond 12 weeks is limited.

Common (most users)

  1. Injection site reactions. Mild redness or irritation, typically resolves within hours.
  2. Increased hunger. Transient (30–60 minutes post-injection) due to ghrelin receptor activation; diminishes with continued use.
  3. Mild fatigue or sleepiness. Often appears in the hour following injection — one reason bedtime dosing is preferred.

Less common (moderate)

  1. Mild headache. Inconsistent across users.
  2. Slight numbness or tingling. Uncommon; related to GH-induced fluid retention.
  3. Mild fluid retention. Inconsistent; typically appears with long-term use.

Serious (rare)

  1. Long-term safety data beyond 12 weeks is limited. Most controlled studies were short-duration.
  2. Theoretical tumor-growth risk. GH/IGF-1 elevation could accelerate pre-existing tumors, so active malignancy is treated as a theoretical exclusion in research contexts.
  3. Severe allergic reactions. Rare and not commonly reported.

Ipamorelin is selective: it does NOT raise cortisol (a problem with GHRP-2 and GHRP-6) and does not affect prolactin or other pituitary hormones. Sustained use is monitored for IGF-1 elevation and glucose tolerance in reported protocols — both rise modestly with sustained GH stimulation.

Does Ipamorelin interact with other drugs?

Ipamorelin's interactions are mostly about avoiding redundancy with other GHRPs (GHRP-2, GHRP-6, MK-677 — same ghrelin receptor) or with direct GH (which bypasses the regulatory feedback that makes ipamorelin safer). Insulin and corticosteroids blunt GH release; time dosing away from meals and steroid administration. No significant drug-drug pharmacokinetic interactions reported.

  1. Insulin and corticosteroids. Both blunt GH release; consider timing dosing away from meals and steroid administration.
  2. Other GH secretagogues (GHRP-2, GHRP-6, MK-677). Combination is redundant via the same receptor; no additive benefit.
  3. Direct human growth hormone (HGH). Combining is generally unnecessary; ipamorelin stimulates endogenous GH and adding exogenous HGH bypasses the regulatory feedback that makes ipamorelin safer.
  4. No significant drug-drug interactions reported in published research.

How should Ipamorelin be stored?

  1. Lyophilized (powder) form: Store at -20°C for long-term storage; refrigerate at 2–8°C for short-term.
  2. Reconstituted solution: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade Ipamorelin remains stable — this page does not state a duration as fact.
  3. Reconstitution uses bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. The reconstituted solution is never frozen.
  5. Ipamorelin is stored protected from light, in the original carton.
  6. A solution that is cloudy, discolored, or contains particles is discarded.

What are the limitations of Ipamorelin research?

Ipamorelin is not FDA-approved for any human use. It was investigated in Phase 2 trials for postoperative ileus by Helsinn Therapeutics; the Beck 2014 trial missed its primary endpoint and reported the drug as well tolerated. FDA's compounding safety-risk list cites a published report of serious adverse events, including death, with intravenous ipamorelin for gastric motility. Most evidence for anti-aging and body composition uses comes from animal models and clinical practice observations rather than controlled human trials. WADA prohibits ipamorelin in sport under Section S2.

Ipamorelin is not FDA-approved for any human use. It was investigated in Phase 2 clinical trials for postoperative ileus by Helsinn Therapeutics. The Beck 2014 trial missed its primary endpoint (25.3 vs 32.6 hours to first tolerated meal, p=0.15) and reported the drug as well tolerated (treatment-emergent adverse events 87.5% vs 94.8% on placebo); a second Phase 2 trial (NCT01280344, n=320) completed with no results posted. FDA's compounding safety-risk list cites a published report of serious adverse events, including death, with intravenous ipamorelin for gastric motility.

Most evidence for ipamorelin's anti-aging and body composition uses comes from animal models, small-scale clinical practice observations, and individual case reports rather than controlled human trials. Long-term safety data beyond 12 weeks is limited.

The World Anti-Doping Agency prohibits ipamorelin in sport under Section S2 (peptide hormones). Research-grade material is sold for laboratory use only and is not approved for human consumption.

Ipamorelin FAQ

How is ipamorelin different from GHRP-2 or GHRP-6?

All three are growth hormone-releasing peptides that activate the ghrelin receptor. The critical difference is selectivity. GHRP-2 and GHRP-6 also raise cortisol, prolactin, and ACTH alongside GH. Ipamorelin raises only GH — no significant effect on other pituitary hormones even at very high doses.

Should I stack ipamorelin with CJC-1295?

It's the most popular and synergistic stack in the GH peptide space. Ipamorelin activates the ghrelin receptor; CJC-1295 activates the GHRH receptor. Combined, they produce greater GH release than either alone. Most research protocols use ipamorelin + CJC-1295 (often without DAC) injected together at bedtime — see the GH Stack page for the combined protocol.

Why bedtime dosing?

Your body releases the majority of its daily GH during the first 90 minutes of deep sleep. Injecting ipamorelin 30–60 minutes before sleep capitalizes on and amplifies this natural GH peak. Dosing at other times still works but produces smaller GH pulses.

Will ipamorelin make me hungry?

Yes, briefly. Ipamorelin activates the ghrelin receptor (ghrelin is the body's primary hunger hormone). Many users report increased appetite for 30–60 minutes after injection. This is part of why bedtime dosing is preferred — you can sleep through the hunger spike. The effect tends to diminish over weeks of consistent use.

Does ipamorelin raise cortisol?

No — this is one of its main advantages over other GHRPs. Even at doses 200x higher than the GH-releasing dose, ipamorelin does not raise cortisol or ACTH. GHRP-2 and GHRP-6 do raise these hormones, which is why ipamorelin is preferred for long-term use.

How long until I see results?

Sleep quality improvements are sometimes reported within 1–2 weeks, though no trial or label has been identified establishing this timeframe. Body composition changes (increased lean mass, reduced fat) are sometimes reported over 8–12 weeks, though no trial or label has been identified establishing this timeframe. IGF-1 elevation can be detected in blood work within days of starting consistent therapy.

Can I take ipamorelin during the day?

Yes, though bedtime alignment with natural GH peaks is most efficient. Some users add a pre-workout dose (30–60 min before training) to amplify exercise-induced GH release. Multiple daily dosing (morning + mid-day + bedtime) is sometimes used for sustained effect, but bedtime alone produces most of the benefit.

Where can I buy ipamorelin?

Ipamorelin is sold by specialty research peptide vendors. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

References

  1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. https://pubmed.ncbi.nlm.nih.gov/9849822/
  2. Wikipedia. Ipamorelin. https://en.wikipedia.org/wiki/Ipamorelin
  3. Johansen PB, Segev Y, Raun K, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13. https://pubmed.ncbi.nlm.nih.gov/10373343/
  4. Andersen NB, Malmlöf K, Johansen PB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001;11(5):266-72. https://pubmed.ncbi.nlm.nih.gov/11735244/
  5. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-77. https://pubmed.ncbi.nlm.nih.gov/10828840/
  6. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6. https://pubmed.ncbi.nlm.nih.gov/10496658/
  7. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. PMID 25331030. NCT00672074. https://pubmed.ncbi.nlm.nih.gov/25331030/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

European Journal of Endocrinology / PubMed · 1998Abstract open
Ipamorelin, the First Selective Growth Hormone Secretagogue →

Raun K, Hansen BS, Johansen NL, et al.

The landmark study establishing Ipamorelin as the first growth hormone secretagogue with high selectivity for GH release — meaning it stimulates GH without significantly raising cortisol, prolactin, or ACTH. In rats, Ipamorelin released GH with potency and efficacy comparable to GHRP-6. In swine, it did not raise ACTH or cortisol beyond the levels seen after GHRH stimulation, even at more than 200 times the GH ED50, while GHRP-6 and GHRP-2 raised both. The abstract gives no percentage figure; all data are animal. This selectivity profile is what distinguishes Ipamorelin from older GHRPs and makes it the preferred GHRP for stacking with GHRH analogs like CJC-1295.

Pharmaceutical Research / PubMed · 1999Abstract open
Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers →

Gobburu JVS, et al.

One of the few human pharmacokinetic studies of Ipamorelin, characterizing how it behaves in the human body. The study modeled the relationship between Ipamorelin plasma concentrations and GH release kinetics in healthy volunteers — confirming that the dose-response relationship seen in animal models translates to humans.

PMC / Translational Andrology and Urology · 2020Open Access
Beyond the Androgen Receptor — The Role of Growth Hormone Secretagogues in Hypogonadal Males →

Sinha DK, Balasubramanian A, Tatem AJ, et al.

A clinical review of GH secretagogues (sermorelin, GHRP-2, GHRP-6, ibutamoren, ipamorelin) in hypogonadal and eugonadal men. Its ipamorelin section covers selective GHS-R1a agonism, rodent postoperative-ileus work, the Beck 2014 trial and mouse body-weight data. The review describes synergy with GHRH for GHRP-2 and ibutamoren, not for ipamorelin, and gives no GH AUC multiple.

Growth HormoneGHRPGHSR AgonistResearch-Grade

Related Peptides

CJC-1295SermorelinTesamorelinMK-677IGF-1 LR3

Related Blends

Tesamorelin + IpamorelinMK-677 + IpamorelinSermorelin + IpamorelinGH StackWolverine Stack

Comparisons

CJC-1295 vs Sermorelin vs Ipamorelin

We may earn commissions from peptide vendor affiliate links.

Have a question about Ipamorelin? Send us an email